Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 913-922

  Stein, R S ^a   Wolff, S N ^a   Greer, J P ^a   Flexner, J M ^a   Goodman, S ^a   Jagasia, M ^a   Brandt, S J ^a   Morgan, D S ^a   Arrowsmith, E ^a   McCurley, T L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute non lymphocytic leukemia; Age; Cytogenetics; Prognostic features

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME DELETION; CHROMOSOME DELETION 16; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; CYTOGENETICS; DONOR; DRUG MEGADOSE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0034851829     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097710     Document Type: Article

References (22)

1. High dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non-lymphocytic leukemia in first remission: A pilot study
2. High dose cytosine arabinoside and daunorubicin as brief consolidation therapy for acute non-lymphocytic leukemia in first remission: An update
3. High dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non-lymphocytic leukemia in first remission: Long term follow-up and results
4. Intensive remission consolidation therapy in the treatment of acute non-lymphocytic leukemia
5. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukemia
6. Double intensive consolidation chemotherapy in adult acute leukemia
7. Varying intensity of postremission therapy in acute myeloid leukemia
8. Long term outcome of high-dose cytarabine based consolidation chemotherapy for adults with acute myelogenous leukemia
9. Intensive postremission chemotherapy in adults with acute myeloid leukemia
10. Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: A pilot study
11. Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
12. Nonparametric estimation from incomplete observations
13. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
14. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases
15. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
16. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
17. Chemotherapy compared with autologous or allogeneic transplantation in the management of acute myeloid leukemia in first remission
18. Chemotherapy v bone marrow transplantation for adults with acute non-lymphocytic leukemia. A 5-year follow-up
19. Treatment of acute myelogenous leukemia. A prospectively controlled trial of bone marrow transplantation versus consolidation chemotherapy
20. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia
21. High dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse